Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data
BUZZ-Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data ** Shares of biotech firm Opus Genetics IRD.O rise 55.3% to $6.75 — highest level since March 2021
** Co says OPGx-BEST1, its experimental gene therapy for BEST1-related retinal diseases, rare inherited eye disorders that cause progressive vision loss and blindness, showed clinically meaningful visual improvements in all five patients treated in an early- to mid-stage study
** Opus says no serious adverse events, dose-limiting toxicities or eye inflammation were observed
** Co reports improvements in visual acuity in 3 of 5 patients and retinal sensitivity improvements in 3 of 4 evaluable patients
** Structural improvements were seen in 4 of 5 patients, including reductions in disease-related retinal lesions and fluid buildup
** Opus over-enrolled the higher-dose cohort to eight patients; topline data expected in Q2 2027
** Including session's move, stock up ~245% YTD
(Reporting by Sahil Pandey in Bengaluru)
Recent news on Opus Genetics
See all newsUS RESEARCH ROUNDUP-Affiliated Managers Group, Goldman Sachs, Vaxcyte
Health Rounds: Experimental eye drops ease night vision problems for drivers
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
Opus Genetics hits 5-year high on positive early- to mid-stage eye disease gene therapy data